AVPR1B
ENSG00000198049
Target class
GPCR
Chromosome
1
Approved drugs
5
Clinical candidates (approved and in development)
7
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- AVPR1B
- Gene name
- Arginine vasopressin receptor 1B
- Gene symbol
- AVPR1B
- Previous gene symbols
- AVPR3
- Protein name
- Vasopressin V1b receptor (V1bR) (AVPR V1b) (AVPR V3) (Antidiuretic hormone receptor 1b) (Vasopressin V3 receptor)
- V1bR
- VPR3
- Gene biotype
- Protein coding
- Gene family
- Arginine vasopressin and oxytocin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 8.24
- Tissue specificity (Gini)
- 0.936
- Tissue specificity (tau)
- 0.994
- KEGG gene identifiers
- hsa:553
- Protein interaction confidence
- 0.875643
- Protein interaction partners
- 14
- R-HSA-388479
- R-HSA-416476
- R-HSA-5619099
- End position
- 206117699
- Start position
- 206106936
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 33713620
- Tissue specificity (tau)
- 0.993932
- Expression inequality (Gini)
- 0.936044
Expression in transcripts per million
- Pituitary
- 8.24
- Brain - Cerebellum
- 0.7
- Brain - Cerebellar Hemisphere
- 0.61
- Stomach
- 0.27
- Small Intestine - Terminal Ileum
- 0.13
Expression in transcripts per million
- Pituitary8.24
- Brain - Cerebellum0.7
- Brain - Cerebellar Hemisphere0.61
- Stomach0.27
- Small Intestine - Terminal Ileum0.13
- Colon - Transverse0.11
- Colon - Sigmoid0.1
- Kidney - Cortex0.1
- Thyroid0.09
- Kidney - Medulla0.09
- Pancreas0.08
- Fallopian Tube0.07
- Uterus0.03
- Brain - Frontal Cortex (BA9)0.03
- Brain - Hypothalamus0.03
- Brain - Anterior cingulate cortex (BA24)0.03
- Brain - Cortex0.03
- Cells - EBV-transformed lymphocytes0.02
- Bladder0.02
- Cervix - Ectocervix0.02
- Cervix - Endocervix0.02
- Spleen0.02
- Minor Salivary Gland0.02
- Testis0.01
- Skin - Not Sun Exposed (Suprapubic)0.01
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0007200
- GO:0007204
- GO:0042127
- GO:0043410
- GO:0046718
- GO:0060732
- GO:0090238
- GO:0005768
- GO:0005794
- GO:0005886
- GO:0005000
- GO:0005080
- GO:0005515
Related records
Trials (277)
- 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy
- 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage
- A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
- A New Check-list Method for Nocturnal Enuresis
- A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
- A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
- A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
- A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
- A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
- ACid Tranexamic or Terlipressin for Initial Emergency Treatment of Mild to seVere hEmoptysis: a Randomized Trial.
- Adding Desmopressin to Tamsulosin for Treatment of BPH
- An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
- An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
- An Eight-Week Study Evaluating the Efficacy of Two Fixed Doses (250 mg Twice Daily and 100 mg Twice Daily) of SSR149415 in Patients With Major Depressive Disorder
- An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
- An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
- Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic
- Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion
- Angiotensin II vs. Vasopressin in Septic Shock
- Argipressin's Influence on Blood Loss During Hepatic Resection
Drugs (8)
- Argipressin tannate Vasopressin receptor agonist
- Desmopressin Vasopressin receptor agonist
- Desmopressin acetate Vasopressin receptor agonist
- Lypressin Vasopressin receptor agonist
- Nelivaptan Vasopressin V1b receptor antagonist
- Terlipressin Vasopressin V1 receptor binding agent
- Vasopressin Vasopressin receptor agonist
- Vasopressin tannate Vasopressin V1b receptor agonist